Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer and his cousin Charles F. Erhart.
Company profile
Ticker
PFE
Exchange
Website
CEO
Albert Bourla
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
356 Royalty Inc. • Agouron Pharmaceuticals, LLC • AH Robins LLC • AHP Manufacturing B.V. • Alpharma Pharmaceuticals LLC • American Food Industries LLC • Amplyx Pharmaceuticals, Inc. • Anacor Pharmaceuticals, LLC • Arena Pharmaceuticals Canada Holdings, L.P. • Arena Pharmaceuticals Development GmbH ...
PFE stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
9 May 24
10-Q
2024 Q1
Quarterly report
8 May 24
8-K
Pfizer Reports First-Quarter 2024 Results
1 May 24
8-K
Submission of Matters to a Vote of Security Holders
29 Apr 24
PX14A6G
Letter to shareholders
16 Apr 24
DEFA14A
Additional proxy soliciting materials
11 Apr 24
DEFA14A
Additional proxy soliciting materials
11 Apr 24
DEFA14A
Additional proxy soliciting materials
11 Apr 24
DEFA14A
Additional proxy soliciting materials
9 Apr 24
DEFA14A
Additional proxy soliciting materials
28 Mar 24
Transcripts
PFE
Earnings call transcript
2024 Q1
1 May 24
PFE
Earnings call transcript
2023 Q4
30 Jan 24
PFE
Earnings call transcript
2023 Q3
31 Oct 23
PFE
Earnings call transcript
2023 Q2
1 Aug 23
PFE
Earnings call transcript
2023 Q2
1 Aug 23
PFE
Earnings call transcript
2023 Q1
2 May 23
PFE
Earnings call transcript
2022 Q4
31 Jan 23
PFE
Earnings call transcript
2022 Q3
1 Nov 22
PFE
Earnings call transcript
2022 Q2
28 Jul 22
PFE
Earnings call transcript
2022 Q1
3 May 22
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Oct 23 | Jul 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 780.00 mm | 780.00 mm | 780.00 mm | 780.00 mm | 780.00 mm | 780.00 mm |
Cash burn (monthly) | 712.33 mm | 120.17 mm | (no burn) | 149.25 mm | (no burn) | (no burn) |
Cash used (since last report) | 1.13 bn | 190.39 mm | n/a | 236.46 mm | n/a | n/a |
Cash remaining | -348.58 mm | 589.61 mm | n/a | 543.54 mm | n/a | n/a |
Runway (months of cash) | -0.5 | 4.9 | n/a | 3.6 | n/a | n/a |
Institutional ownership, Q4 2023
48.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2490 |
Opened positions | 253 |
Closed positions | 631 |
Increased positions | 719 |
Reduced positions | 1372 |
13F shares | Current |
---|---|
Total value | 74.86 tn |
Total shares | 2.75 bn |
Total puts | 17.96 mm |
Total calls | 34.13 mm |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 506.52 mm | $14.58 tn |
STT State Street | 287.48 mm | $8.28 tn |
Wellington Management | 239.21 mm | $6.89 tn |
Capital World Investors | 173.39 mm | $4.99 tn |
Charles Schwab Investment Management | 104.25 mm | $2.99 tn |
MS Morgan Stanley | 82.11 mm | $2.36 tn |
Massachusetts Financial Services | 68.51 mm | $1.97 tn |
NTRS Northern Trust | 59.81 mm | $1.72 tn |
LGEN Legal & General | 49.62 mm | $1.43 tn |
BK Bank Of New York Mellon | 44.09 mm | $1.27 tn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 May 24 | Jennifer B. Damico | Phantom Stock Units SSP Common Stock | Grant | Acquire A | No | No | 28.82 | 49 | 1.41 k | 28,346 |
15 May 24 | Albert Bourla | Phantom Stock Units SSP Common Stock | Grant | Acquire A | No | No | 28.82 | 18 | 518.76 | 668,625 |
30 Apr 24 | Jennifer B. Damico | Phantom Stock Units SSP Common Stock | Grant | Acquire A | No | No | 25.62 | 55 | 1.41 k | 27,920 |
30 Apr 24 | Albert Bourla | Phantom Stock Units SSP Common Stock | Grant | Acquire A | No | No | 25.62 | 20 | 512.40 | 659,681 |
25 Apr 24 | Blaylock Ronald E | Phantom Stock Units Common Stock | Grant | Acquire A | No | No | 25.26 | 8,115.598 | 205.00 k | 58,627.024 |
News
4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
17 May 24
European Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech
17 May 24
'Moderna Wins Case In Patent Dispute With Pfizer And BioNTech Over Covid Jab; Decision Is A Boon For The mRNA-Vaccine Maker In Its Legal Fight To Recoup Pandemic Profits From Rivals' - Financial Times
17 May 24
GSK Completely Exits Sensodyne Toothpaste Maker Haleon In $1.6B Sale
17 May 24
Spotlight on Pfizer: Analyzing the Surge in Options Activity
16 May 24
Press releases
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
16 May 24
ViiV Healthcare Announces Health Canada Approval for APRETUDE (Cabotegravir tablets and extended release injectable suspension) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV
13 May 24
Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting
13 May 24
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
8 May 24
Pfizer Announces New Chief Strategy and Innovation Officer
6 May 24